Literature DB >> 16340739

Autoimmune pancreatitis and complement activation system.

Takashi Muraki1, Hideaki Hamano, Yasuhide Ochi, Kenichi Komatsu, Yuichi Komiyama, Norikazu Arakura, Kaname Yoshizawa, Masao Ota, Shigeyuki Kawa, Kendo Kiyosawa.   

Abstract

OBJECTIVES: Autoimmune pancreatitis is characterized by increased serum level of IgG4, but its pathogenesis has not been fully elucidated. Because this disease is occasionally associated with decreased levels of complements, we sought to clarify which complement activation system was operating in its active state.
METHODS: We measured serum levels of complements, mannose-binding lectin, and circulating immune complex in patients with autoimmune pancreatitis, patients with chronic pancreatitis, and healthy controls.
RESULTS: We found high serum circulating immune complex values, which decreased significantly after corticosteroid therapy. In patients with autoimmune pancreatitis, elevated levels of circulating immune complex, as determined by C1q assay, were significantly associated with increased serum levels of IgG1 and decreased levels of C4, as well as with a tendency toward decreased levels of C3. There were no significant differences in the serum levels of mannose-binding lectin or in the frequency of a mutant allele of mannose-binding lectin between patients with autoimmune pancreatitis and those with chronic calcifying pancreatitis. Furthermore, corticosteroid therapy had no effect on the level of mannose-binding lectin.
CONCLUSIONS: Autoimmune pancreatitis exhibits a high serum circulating immune complex values in its active state, which links to a complement activation system with a classic pathway rather than the mannose-binding lectin pathway or alternative pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16340739     DOI: 10.1097/01.mpa.0000188308.75043.e4

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  49 in total

Review 1.  Autoimmune pancreatitis and IgG4-related sclerosing disease.

Authors:  Terumi Kamisawa; Kensuke Takuma; Naoto Egawa; Koji Tsuruta; Tsuneo Sasaki
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-15       Impact factor: 46.802

2.  The proteome of postsurgical pancreatic juice.

Authors:  Giovanni Marchegiani; Joao A Paulo; Klaus Sahora; Carlos Fernández-Del Castillo
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

Review 3.  Acute recurrent pancreatitis: an autoimmune disease?

Authors:  Raffaele Pezzilli
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

4.  Hypocomplementemia of unknown etiology: an opportunity to find cases of IgG4-positive multi-organ lymphoproliferative syndrome.

Authors:  Takako Saeki; Tomoyuki Ito; Hajime Yamazaki; Naofumi Imai; Shinichi Nishi
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 2.631

Review 5.  Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis.

Authors:  Kazuichi Okazaki; Kazushige Uchida; Toshiro Fukui
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

6.  Autoimmune Pancreatitis and IgG4-Related Disease: The Storiform Discovery to Treatment.

Authors:  Kazuichi Okazaki
Journal:  Dig Dis Sci       Date:  2019-09       Impact factor: 3.199

Review 7.  Immunology of IgG4-related disease.

Authors:  E Della-Torre; M Lanzillotta; C Doglioni
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

Review 8.  Diagnostic and treatment workup for IgG4-related disease.

Authors:  Mary Abraham; Arezou Khosroshahi
Journal:  Expert Rev Clin Immunol       Date:  2017-07-24       Impact factor: 4.473

9.  Autoimmune Pancreatitis.

Authors:  Gyanprakash A Ketwaroo; Sunil Sheth
Journal:  Gastroenterol Rep       Date:  2013-04-04       Impact factor: 3.651

10.  Decreased production of immunoglobulin M and A in autoimmune pancreatitis.

Authors:  Masashi Taguchi; Yasuyuki Kihara; Yoshikuni Nagashio; Mitsuyoshi Yamamoto; Makoto Otsuki; Masaru Harada
Journal:  J Gastroenterol       Date:  2009-07-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.